Amyris (NASDAQ:AMRS) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Wednesday.
Other equities research analysts have also recently issued reports about the stock. B. Riley set a $10.00 price target on shares of Amyris and gave the stock a “buy” rating in a research report on Sunday, May 20th. HC Wainwright set a $15.00 price target on shares of Amyris and gave the stock a “buy” rating in a research report on Tuesday, May 15th. ValuEngine upgraded shares of Amyris from a “hold” rating to a “buy” rating in a research note on Monday, May 7th. Finally, Zacks Investment Research upgraded shares of Amyris from a “hold” rating to a “buy” rating and set a $7.50 price objective on the stock in a research note on Wednesday, April 25th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $9.13.
Shares of NASDAQ:AMRS opened at $5.50 on Wednesday. The company has a current ratio of 0.67, a quick ratio of 0.62 and a debt-to-equity ratio of -0.35. Amyris has a one year low of $1.86 and a one year high of $7.30. The stock has a market cap of $272.46 million, a price-to-earnings ratio of -1.80 and a beta of 0.07.
Amyris (NASDAQ:AMRS) last issued its quarterly earnings results on Monday, May 14th. The biotechnology company reported ($1.79) EPS for the quarter, missing the consensus estimate of ($0.48) by ($1.31). The business had revenue of $23.00 million for the quarter, compared to analysts’ expectations of $24.12 million. During the same quarter in the previous year, the business earned ($0.13) earnings per share. Amyris’s quarterly revenue was up 77.2% on a year-over-year basis. equities analysts forecast that Amyris will post -1.92 EPS for the current fiscal year.
In other news, major shareholder (Mauritius) Pte Ltd Maxwell sold 95,162 shares of the business’s stock in a transaction dated Monday, May 7th. The shares were sold at an average price of $6.54, for a total transaction of $622,359.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 21.80% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the company. Compagnie Lombard Odier SCmA increased its stake in shares of Amyris by 60.0% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 104,000 shares of the biotechnology company’s stock worth $390,000 after purchasing an additional 39,000 shares during the last quarter. Hudson Bay Capital Management LP acquired a new position in shares of Amyris during the 4th quarter worth about $451,000. Crown Advisors Management Inc. acquired a new position in Amyris in the 1st quarter valued at about $669,000. B. Riley Financial Inc. acquired a new position in Amyris in the 1st quarter valued at about $294,000. Finally, Tibra Equities Europe Ltd acquired a new position in Amyris in the 1st quarter valued at about $295,000. Institutional investors own 23.72% of the company’s stock.
Amyris Company Profile
Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.